Saturday, September 30, 2023
No Result
View All Result
  • Media
Support Us
Macdonald-Laurier Institute
  • Home
  • About
    • Who We Are
    • Who Makes MLI Work
    • Tenth Anniversary
  • Experts
    • Experts Directory
    • In Memoriam
  • Issues
    • Domestic Policy
      • Agriculture and Agri-Food
      • Canada’s Political Tradition
      • Economic policy
      • Health Care
      • Innovation
      • Justice
      • Social issues
      • Telecoms
    • Energy Policy
      • Energy
      • Environment
    • Foreign Policy
      • Foreign Affairs
      • National Defence
      • National Security
    • Indigenous Affairs
  • Projects
    • The Great Energy Crisis
    • Centre for Advancing Canada’s Interests Abroad
    • Dragon at the Door
    • Canada and the Indo-Pacific Initiative
    • The Transatlantic Program
    • DisInfoWatch.org
    • Competition Policy in Canada
    • Speak for Ourselves
    • Justice Report Card
    • COVID Misery Index
      • Provincial COVID Misery Index
      • Beyond Lockdown
      • COVID and after: A mandate for recovery
    • Indigenous Prosperity at a Crossroads
      • Aboriginal Canada and Natural Resources
    • Past Projects
      • The Eavesdropping Dragon: Huawei
      • Talkin’ in the Free World with Mariam Memarsadeghi
      • An Intellectual Property Strategy for Canada
      • Munk Senior Fellows
      • A Mandate for Canada
      • Confederation Series
      • Fiscal Reform
      • The Canadian Century project
      • Fixing Canadian health care
      • Internal trade
      • From a mandate for change
      • Size of government in Canada
      • Straight Talk
      • Labour Market Report
      • Leading Economic Indicator
  • Events
    • Upcoming Events
    • Past Events
      • MLI Dinners
      • Great Canadian Debates
  • Latest News
  • Libraries
    • Inside Policy
    • Papers
    • Commentary
    • Columns
    • Books
    • Video
  • Home
  • About
    • Who We Are
    • Who Makes MLI Work
    • Tenth Anniversary
  • Experts
    • Experts Directory
    • In Memoriam
  • Issues
    • Domestic Policy
      • Agriculture and Agri-Food
      • Canada’s Political Tradition
      • Economic policy
      • Health Care
      • Innovation
      • Justice
      • Social issues
      • Telecoms
    • Energy Policy
      • Energy
      • Environment
    • Foreign Policy
      • Foreign Affairs
      • National Defence
      • National Security
    • Indigenous Affairs
  • Projects
    • The Great Energy Crisis
    • Centre for Advancing Canada’s Interests Abroad
    • Dragon at the Door
    • Canada and the Indo-Pacific Initiative
    • The Transatlantic Program
    • DisInfoWatch.org
    • Competition Policy in Canada
    • Speak for Ourselves
    • Justice Report Card
    • COVID Misery Index
      • Provincial COVID Misery Index
      • Beyond Lockdown
      • COVID and after: A mandate for recovery
    • Indigenous Prosperity at a Crossroads
      • Aboriginal Canada and Natural Resources
    • Past Projects
      • The Eavesdropping Dragon: Huawei
      • Talkin’ in the Free World with Mariam Memarsadeghi
      • An Intellectual Property Strategy for Canada
      • Munk Senior Fellows
      • A Mandate for Canada
      • Confederation Series
      • Fiscal Reform
      • The Canadian Century project
      • Fixing Canadian health care
      • Internal trade
      • From a mandate for change
      • Size of government in Canada
      • Straight Talk
      • Labour Market Report
      • Leading Economic Indicator
  • Events
    • Upcoming Events
    • Past Events
      • MLI Dinners
      • Great Canadian Debates
  • Latest News
  • Libraries
    • Inside Policy
    • Papers
    • Commentary
    • Columns
    • Books
    • Video
No Result
View All Result
Macdonald-Laurier Institute

The kindest cut: Excising the Patented Medicine Prices Review Board from the Canadian body politic

The Patented Medicine Prices Review Board (PMPRB) harms drug access rather than promoting it.

June 2, 2022
in Domestic Policy Program, Health, Health care - papers, Papers, Richard Owens
Reading Time: 3 mins read
A A

By Richard C. Owens, Rebecca Rosenberg, and Haya Sardar
June 2, 2022

PDF of paper

Executive Summary

Canada’s drug price controls, implemented through the Patented Medicine Prices Review Board (PMPRB), hurt both innovation in the life sciences sector and Canadians’ access to pharmaceuticals. The PMPRB was created in 1987 as an expedient to placate opposition to the passage of much-needed intellectual property (IP) law reforms. Pharmaceutical science has changed dramatically since then; the PMPRB has not.

In 2018 the federal government attempted to modernize the PMPRB through ill-conceived New Regulations. While the government appears to have bowed to constitutional inevitability and withdrawn key portions of the New Regulations, there is no guarantee that similar regulations will not be promulgated in their place. As such, it is important to assess the fundamental problems with them.

Like the bulk of the New Regulations, the PMPRB itself has no constitutional foundation. It exceeds the powers of the federal government, amounting to industrial price controls, which are a provincial, not a federal, power. Moreover, even if the PMPRB edifice continued to stand on its shaky constitutional footings, case law makes clear that the Patent Act doesn’t authorize price controls as PMPRB applies them.

To the PMPRB and its defenders, drugs are products uniquely inimical to distribution in a free market. But drugs are also goods, subject to market scarcity and value calculations, and their prices are normal prices. PMPRB price controls, like any price control, limit supply and availability and curtail the development of new products. If government and the courts want to encourage Canadians’ good health, they should stop supporting price controls.

A 2018 MLI study addressed the question of whether Canada can lower prices and simply rely on the US for its innovation. But that is not a sustainable approach to pharmaceutical innovation in Canada, nor healthcare. Like the rest of the world, we exploit the US consumer to fund our drug supplies. As a result, the US itself is now considering its own price controls. If implemented, they would effectively slaughter the world’s pharmaceutical golden goose.

Leadership is urgently needed to re-balance cost-sharing internationally. Canada can demonstrate that leadership, benefiting its innovation economy and leading the world toward a more equitable allocation of the costs and benefits of pharmaceutical science. A low-price regime will inevitably hurt the life sciences sector and adversely impact industry employment and, ultimately, the Canadian economy. US prices should be reduced as other nations, including Canada, shoulder a more proper share of their economic burden.

Life sciences patent monopolies bring into being the very things to which they apply. Profits are well-earned and a necessary incentive. A patent on a successful drug offers the potential for a financial prize. Only with such a promise can the economy of drug discovery function. Innovation can never be centrally planned or controlled; it arises from sound economic, institutional and legal conditions that we mess with at our peril.

Evidence also strongly suggests that a pharmaceutical market without price controls works well. Competition among therapies, as well as other market constraints on pricing power, are among the factors that limit pricing freedom. Without price controls, Canada would benefit from greatly improved access to new drugs and therapies.

By preserving price controls, we depress our life sciences industry and hurt health care. Worse still, the PMPRB and its adherents have political incentives to demonize and diminish the life sciences sector, since the more it grows and contributes, the harder it would be to justify confiscatory PMPRB price controls. We could hardly have a policy better aimed at undermining Canadian science and industry than institutionalized drug price controls.

The PMPRB alleges that it saves Canadians money. But it is never clear how much. The PMPRB is a clumsy tool that harms drug access rather than promoting it. Price ceilings limit drug revenues, which reduce R&D spending on drug discovery and make Canada an undesirable location for conducting clinical trials and launching new drugs. Importantly, removing price controls will have little impact on most drug purchases in Canada. It is time to scrap the PMPRB altogether.

Share this:
Tags: drug pricingPMPRBRichard Owens
Previous Post

The agency created to protect global energy security isn’t: Heather Exner-Pirot in the Vancouver Sun

Next Post

MLI paper finds Canada’s drug price controls hurt both innovation and Canadians’ access to medication

Related Posts

Canada’s systemic failure to manage complex public policy issues
Papers

Canada’s governance crisis

September 28, 2023
Canada’s systemic failure to manage complex public policy issues
Releases

Canada’s systemic failure to manage complex public policy issues

September 28, 2023
A new Digital Services Tax would harm consumers and antagonize trade partners: David Collins for Inside Policy
Inside Policy

A new Digital Services Tax would harm consumers and antagonize trade partners: David Collins for Inside Policy

September 27, 2023
Next Post
MLI paper finds Canada’s drug price controls hurt both innovation and Canadians’ access to medication

MLI paper finds Canada’s drug price controls hurt both innovation and Canadians’ access to medication

Newsletter Signup

Follow us on

Macdonald-Laurier Institute

323 Chapel Street, Suite #300
Ottawa, Ontario, K1N 7Z2 Canada

613.482.8327

info@macdonaldlaurier.ca
MLI directory

Support Us

Support the Macdonald-Laurier Institute to help ensure that Canada is one of the best governed countries in the world. Click below to learn more or become a sponsor.

Support Us

  • Inside Policy Magazine
  • Annual Reports
  • Jobs
  • Privacy Policy

© 2021 Macdonald-Laurier Institute. All Rights reserved.

No Result
View All Result
  • Home
  • About
    • Who We Are
    • Who Makes MLI Work
    • Tenth Anniversary
  • Experts
    • Experts Directory
    • In Memoriam
  • Issues
    • Domestic Policy
      • Agriculture and Agri-Food
      • Canada’s Political Tradition
      • Economic policy
      • Health Care
      • Innovation
      • Justice
      • Social issues
      • Telecoms
    • Energy Policy
      • Energy
      • Environment
    • Foreign Policy
      • Foreign Affairs
      • National Defence
      • National Security
    • Indigenous Affairs
  • Projects
    • The Great Energy Crisis
    • Centre for Advancing Canada’s Interests Abroad
    • Dragon at the Door
    • Canada and the Indo-Pacific Initiative
    • The Transatlantic Program
    • DisInfoWatch.org
    • Competition Policy in Canada
    • Speak for Ourselves
    • Justice Report Card
    • COVID Misery Index
      • Provincial COVID Misery Index
      • Beyond Lockdown
      • COVID and after: A mandate for recovery
    • Indigenous Prosperity at a Crossroads
      • Aboriginal Canada and Natural Resources
    • Past Projects
      • The Eavesdropping Dragon: Huawei
      • Talkin’ in the Free World with Mariam Memarsadeghi
      • An Intellectual Property Strategy for Canada
      • Munk Senior Fellows
      • A Mandate for Canada
      • Confederation Series
      • Fiscal Reform
      • The Canadian Century project
      • Fixing Canadian health care
      • Internal trade
      • From a mandate for change
      • Size of government in Canada
      • Straight Talk
      • Labour Market Report
      • Leading Economic Indicator
  • Events
    • Upcoming Events
    • Past Events
      • MLI Dinners
      • Great Canadian Debates
  • Latest News
  • Libraries
    • Inside Policy
    • Papers
    • Commentary
    • Columns
    • Books
    • Video

© 2021 Macdonald-Laurier Institute. All Rights reserved.

IDEAS CHANGE THE WORLD!Have the latest Canadian thought leadership delivered straight to your inbox.
First Name
Last Name
Email address

No thanks, I’m not interested.